Alpha 2.0
Login Register
» Journals » Can Urol Assoc J

Canadian Urological Association Journal

The Canadian Urological Association Journal (CUAJ) is the official publication of the Association des urologues du Canada. It is a peer-reviewed journal that focuses on urological research, clinical practice, and education. The CUAJ publishes original articles, reviews, case reports, and editorials, covering a wide range of topics in urology. It serves as a valuable resource for urologists, researchers, and healthcare professionals interested in advancements and innovations in the field of urology.
Details
Abbr. Can Urol Assoc J
Start 2007
End Continuing
Frequency Monthly
p-ISSN 1911-6470
e-ISSN 1920-1214
Country Canada
Languages English
French
Specialty Urology
Metrics
h-index / Ranks: 7705 47
SJR / Ranks: 8806 507
CiteScore / Ranks: 9213 2.70
JIF / Ranks: 5372 1.9
Recent Articles
1.
Erratum - Title change for MIBC Guideline
Can Urol Assoc J . 2025 Mar; 19(3):E128. PMID: 40036972
No abstract available.
2.
Advocating for patients with urinary retention and lower urinary tract obstruction regardless of etiology "Establishing maximal wait times for urologic surgery in Canada in 2024" (Can Urol Assoc J 2024;18:376-8)
Rourke K, Hoy N, Shahrour W, Chan G, Welk B, Doiron R, et al.
Can Urol Assoc J . 2025 Mar; 19(3):E125-E126. PMID: 40036970
No abstract available.
3.
Use of AI (GPT-4)-generated multiple-choice questions for the examination of surgical subspecialty residents: Report of feasibility and psychometric analysis
Kim J, Chua M, Lorenzo A, Rickard M, Andreacchi L, Kim M, et al.
Can Urol Assoc J . 2025 Mar; PMID: 40031953
Introduction: Multiple-choice questions (MCQs) are essential in medical education and widely used by licensing bodies. They are traditionally created with intensive human effort to ensure validity. Recent advances in AI,...
4.
Promoting wellness in urology residency programs: Moving beyond tokenism
Dhalla R, Lee J, Krakowsky Y
Can Urol Assoc J . 2025 Mar; PMID: 40031952
No abstract available.
5.
Assessing the methodologic heterogeneity of Canadian Urological Association guidelines: Adoption of the GRADE approach (2018-2023)
Ding M, Gandhi V, Gonzalez-Padilla D, Dahm P
Can Urol Assoc J . 2025 Mar; PMID: 40031951
Introduction: The Canadian Urological Association (CUA) has a longstanding tradition of developing evidence-based guidelines. We conducted this study to assess the heterogeneity of the CUA's guideline methodology for developing recommendations...
6.
Lidocaine solution vs. lidocaine gel instillation for pain management during intravesical botulinum injections
Negrean C, Ross J, Yu W, Maciejewski C, Vigil H, Hickling D
Can Urol Assoc J . 2025 Mar; PMID: 40031950
Introduction: Most Canadian urologists use lidocaine solution prior to botulinium toxin (BoNT) administration; however, this requires additional time. The aim was to compare pain scores in patients undergoing office-based BoNT...
7.
Association of marginalization and PSMA-PET in prostate cancer: An analysis of the Ontario PSMA-PET Registry for Recurrent Prostate Cancer
Tan V, Metser U, Rashid M, Langer D, MacCrostie P, Green B, et al.
Can Urol Assoc J . 2025 Mar; PMID: 40031949
Introduction: Prostate-specific membrane antigen positron emission tomography (PSMA PET) is a new standard for the imaging of high-risk or recurrent prostate cancer. While marginalization disparities exist for prostate cancer, less...
8.
Using real-world, population-level data to assess the uptake of active surveillance for low-grade prostate cancer before and after the release of clinical guidelines
Cheung D, Martin L, Timilshina N, Komisarenko M, Richard P, Alibhai S, et al.
Can Urol Assoc J . 2025 Mar; PMID: 40031948
Introduction: Clinical guidelines recommend active surveillance (AS) as the preferred strategy for men with localized grade group (GG) 1 prostate cancer (PCa). We determined if the percentage of GG1 PCa...
9.
Association of absolute amount of pattern 4 disease on prostate biopsy with oncologic outcomes in intermediate-risk prostate cancer: A systematic review
Soon M, Morgan S, Lavallee L, Breau R, Flood T, Corkum M
Can Urol Assoc J . 2025 Mar; PMID: 40031947
Introduction: Managing intermediate-risk prostate cancer (IRPC) is challenging due to the heterogeneity in patient outcomes within this risk category. Evaluating the absolute amount of Gleason pattern 4 disease (GP4) at...
10.
Prostate cancer screening in transgender patients: Why current Canadian screening policies need to be better tailored to our patients
Nguyen D, Ahmad I, Al-Daqqaq Z, Rosella L, Hird A, Wallis C, et al.
Can Urol Assoc J . 2025 Mar; PMID: 40031946
No abstract available.